8 active not recruiting, 5 completed, 3 recruiting, 2 terminated. 8 Phase 3, 7 Not applicable, 7 Phase 2.
Follow Borstkanker Onderzoek Groep: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects eChemoCoach - Breast Cancer, eHealth | Not applicable | Not yet recruiting | Noordwest Ziekenhuisgroep | 746 | 2025-06-01 | 2024-05-21 |
| Postoperative Re-irradiaTion With and Without HYPERthermia, or Surgery Only: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups. - Locoregional Recurrence, Breast Cancer | Recruiting | Amsterdam UMC, location VUmc | 500 | 2024-02-01 | 2026-07-16 | |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Fasting Mimicking diet program - Fasting Mimicking Diet, HER2-negative Breast Cancer | Phase 3 | Suspended | Leiden University Medical Center | 10 | 2023-03-17 | 2023-11-22 |
| Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer personalized surveillance plans (PSP) and personalized aftercare plans (PAP) - Breast Cancer, Breast Cancer Female | Enrolling by invitation | Comprehensive Cancer Centre The Netherlands | 1040 | 2023-03-06 | 2023-08-03 | |
| DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy Omission of radiotherapy - Breast Cancer | Not applicable | Recruiting | The Netherlands Cancer Institute | 595 | 2022-10-07 | 2025-03-26 |
| SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) Alpelisib 150 MG Oral Tablet [Piqray], Fulvestrant - Neoplasm, Breast, Congenital, Familial and Genetic Disorders | Phase 2 | Active not recruiting | Borstkanker Onderzoek Groep | 130 | 2022-06-02 | 2026-05-22 |
| TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer trifluridine/tipiracil - Breast Neoplasm, Chemotherapy Effect | Phase 2 | Completed | Borstkanker Onderzoek Groep | 52 | 2020-09-25 | 2026-05-22 |
| Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Letrozole, Chemotherapy, Ribociclib plus letrozole - Breast Neoplasms | Phase 2 | Active not recruiting | Borstkanker Onderzoek Groep | 100 | 2019-06-15 | 2026-10-01 |
| Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study PTC-Pz - Breast Cancer | Phase 2 | Active not recruiting | Borstkanker Onderzoek Groep | 462 | 2019-02-27 | 2026-10-05 |
| Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer Denosumab 120 mg, Denosumab 60 mg - Breast Neoplasms | Phase 2 | Withdrawn | Borstkanker Onderzoek Groep | 2018-02-01 | 2020-01-18 | |
| Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer CDK 4/6 inhibitor, Non-Steroidal Aromatase Inhibitor, Fulvestrant - Breast Neoplasm Female | Phase 3 | Active not recruiting | Borstkanker Onderzoek Groep | 1050 | 2017-11-09 | 2026-05-20 |
| Management of Low-risk (Grade I and II) DCIS Standard treatment, digital mammography, radiotherapy - DCIS | Not applicable | Active not recruiting | The Netherlands Cancer Institute | 2500 | 2017-02-13 | 2026-01-26 |
| Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy Sentinel lymph node procedure - Breast Neoplasms | Not applicable | Completed | Maastricht University Medical Center | 1644 | 2015-05-18 | 2026-09-02 |
| Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy Completion axillary treatment - Breast Neoplasms | Not applicable | Terminated | Maastricht University Medical Center | 52 | 2014-06-01 | 2018-05-09 |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane Everolimus plus Exemestane - Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer | Not applicable | Unknown | Amsterdam UMC, location VUmc | 175 | 2014-03-01 | 2019-10-14 |
| DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer Fasting mimicking diet - Fasting Mimicking Diet, Breast Cancer | Phase 2 / Phase 3 | Completed | Leiden University Medical Center | 131 | 2014-02-01 | 2019-10-24 |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 PTC+Pertuzumab, FEC-T+Pertuzumab - Breast Cancer, HER2 Positive | Phase 3 | Active not recruiting | The Netherlands Cancer Institute | 437 | 2013-12-01 | 2024-03-29 |
| Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel - Breast Cancer | Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 304 | 2013-07-01 | 2025-11-26 |
| Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer upfront breast surgery, systemic therapy - Metastatic Breast Cancer | Phase 3 | Terminated | Jeroen Bosch Ziekenhuis | 10 | 2012-02-01 | 2014-02-04 |
Showing 20 of 24. Sign in to see all of them.
Breast Neoplasms (20) · Carcinoma, Intraductal, Noninfiltrating (2) · Neoplasm Metastasis (2) · Carcinoma, Ductal, Breast (1) · Genetic Diseases, Inborn (1) · Hyperthermia (1) · Pathologic Complete Response (1)
Cyclophosphamide (3) · Letrozole (3) · Paclitaxel (3) · Anastrozole (2) · Carboplatin (2) · Doxorubicin (2) · Fulvestrant (2) · exemestane (2) · Alpelisib (1) · Bevacizumab (1) · Capecitabine (1) · Denosumab (1) · Docetaxel (1) · Drug Therapy (1) · Epirubicin (1)
Netherlands (23) · Belgium (3) · Ireland (3) · Switzerland (3) · France (2) · Greece (2) · Italy (2) · Portugal (2) · Spain (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Cyprus (1)
Gerrit-Jan Liefers, MD PhD (2) · Hans JW de Wilt, MD, PhD (2) · Judith R Kroep, MD PhD (2) · Marjolein L Smidt, MD, PhD (2) · A E van Leeuwen-Stok, PhD (1) · A. E van Leeuwen-Stok, PhD (1) · A. Elise van Leeuwen-Stok, PhD (1) · A. Jager, MD, PhD (1) · A.C. Voogd, dr (1) · Boon Chua (1) · Desiree Van Den Bongard, Dr (1) · Emmanouil Saloustros (1) · Epie Boven, Prof.dr. MD (1)
PMID 38979716, PMID 22469291, PMID 26335105, PMID 26738606, PMID 28668073, PMID 30413379, PMID 30458732, PMID 31455425, PMID 32203696, PMID 32576828, PMID 33084020, PMID 33179154, PMID 34014249, PMID 35934006, PMID 36892723, PMID 37964214, PMID 38588682, PMID 40017682, PMID 40365927, PMID 40908356, PMID 41207182, PMID 41270788, PMID 41712229, PMID 41713473, PMID 41888754
2017 (2), 2009 (1), 2016 (1)